---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-007521"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:24:45.408598+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# INmune Bio treats first patient in Phase II portion of INKmune trial for metastatic prostate cancer at VA hospital

## Summary
- First patient treated in Phase II portion of Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC) at West LA VA Medical Center.
- Patient received the medium dose of INKmune, an NK cell therapy, expanding the ongoing trial to the VA health system.
- Approximately 15,000 Veterans diagnosed with prostate cancer annually; 200,000+ Veterans are survivors.
- Principal investigator Dr. Matthew Rettig notes the therapy is given as outpatient with minimal side effects.

## SEC filing metadata
- accession: 0001213900-25-007521
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/0001213900-25-007521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/ea0228960-8k_inmunebio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-007521
- JSON: https://secwatch.observer/filing/0001213900-25-007521.json
- Plain text: https://secwatch.observer/filing/0001213900-25-007521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.